Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FJMX9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,523
Award facts
- Contract value 100% obligated
- $19,522.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,522.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The award, issued on December 3, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with its parent IDC under PPV-G GEN V carrying a $499,999,999 ceiling value through December 31, 2036. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables across multiple therapeutic categories. Through its established performance on numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, DMS Pharmaceutical Group demonstrates the capability to fulfill the diverse and specialized pharmaceutical requirements supporting Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FJMX9?
SPE2DR26FJMX9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FJMX9 worth?
The government has obligated $19,523 on SPE2DR26FJMX9.
Is contract SPE2DR26FJMX9 an order under another contract?
Yes. SPE2DR26FJMX9 is a delivery order under SPE2DR25D9644, an indefinite delivery contract.
Was contract SPE2DR26FJMX9 competed?
The extent of competition for SPE2DR26FJMX9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award